Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Profesionales de la salud / / / /
|
Accelerated Partial Breast Irradiation (APBI): An Analysis of Variables Associated with Late Toxicity after HDR Interstitial Brachytherapy
Presenter: S. KaufmanPresenter's Affiliation: Radiation Oncology, Tufts/ Brown Universities, Boston, MA, Radiation Oncology, Virginia Commonwealth University, Richmond, VAType of Session: ScientificBackground There is currently limited data... |
|
|
An Update of the Phase III Trial Comparing Whole-Pelvic (WP) to Prostate Only (PO) Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression (TAS): Updated Analysis of RTOG 94-13
Presenter: C. A. LawtonPresenter's Affiliation: Medical College of WisconsinType of Session: ScientificBackground There is much interest in both the use and timing of androgen suppression during external beam radiation treatment of intermediate- to... |
|
|
ASTRO Patient Summary: An Update of the Phase III Trial Comparing Whole-Pelvic (WP) to Prostate Only (PO) Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression (TAS): Updated Analysis of RTOG 94-13
An Update of the Phase III Trial Comparing Whole-Pelvic (WP) to Prostate Only (PO) Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression (TAS): Updated Analysis of RTOG 94-13 Prostate cancer is often treated with radiation and hormone... |
|
|
ASTRO Patient Summary: Comparison of 30 Gy versus 20 Gy Involved Field Radiotherapy After Two Versus Four Cycles ABVD in Early Stage Hodgkin's Lymphoma: Interim Analysis of the German Hodgkin Study Group Trial HD10
This study looked at patients with early stage (I and II) Hodgkin's disease. There is some controversy over the dose of radiation therapy and the number of cycles of standard chemotherapy (ABVD regimen) these patients should receive. Patients were... |
|
|
ASTRO Patient Summary: Lumpectomy Plus Tamoxifen or Arimidex With or Without Whole Breast Irradiation in Women with Favorable Early Breast Cancer
Lumpectomy Plus Tamoxifen or Arimidex With or Without Whole Breast Irradiation in Women with Favorable Early Breast Cancer This presentation reviewed a recent study involving postmenopausal women with early stage, hormone receptor positive breast... |
|
|
ASTRO Patient Summary: Phase III Randomized Study of Adjuvant Radiation Therapy versus Observation in Patients with Pathologic T3 Prostate Cancer (SWOG 8794)
Phase III Randomized Study of Adjuvant Radiation Therapy versus Observation in Patients with Pathologic T3 Prostate Cancer (SWOG 8794) This study looked at prostate cancer patients who were found to have "adverse pathologic features" (invasion... |
|
|
ASTRO Patient Summary: Preoperative Chemo-radiotherapy (CT-RT) Improves Local Control in T3-T4 Rectal Cancers: Results of the FFCD 9203 Randomized Trial
Preoperative Chemo-radiotherapy (CT-RT) Improves Local Control in T3-T4 Rectal Cancers: Results of the FFCD 9203 Randomized Trial This study examined patients with T3 or T4 rectal adenocarcinoma with no metastases. Patients were assigned to receive... |
|
|
ASTRO Patient Summary: Surveillance Should Be the Standard Approach in Patients with Stage I Seminoma
Surveillance Should Be the Standard Approach in Patients with Stage I Seminoma Stage I testicular cancer (seminoma) is managed by first-line surgery (orchiectomy) and then, most commonly, observation without additional therapy. Many centers offer... |
|
|
Comparison of 30 Gy versus 20 Gy Involved Field Radiotherapy After Two Versus Four Cycles ABVD in Early Stage Hodgkin's Lymphoma: Interim Analysis of the German Hodgkin Study Group Trial HD10
Presenter: R.P. MullerPresenter's Affiliation: Medical University of Vienna, AustriaType of Session: PlenaryBackground Combined modality treatment consisting of few cycles of chemotherapy, usually ABVD, followed by involved field radiotherapy... |
|
|
Does Pelvis and Prostate Radiation Therapy Compared to Prostate Radiation Therapy Alone Improve Survival in Patients with Non Metastatic Prostate Carcinoma? Preliminary Results of the Prospective Randomized GETUG 01 Trial
Presenter: P. PommierPresenter's Affiliation: Centre Leon Berard, Lyon, FranceType of Session: ScientificBackground There has been ongoing controversy regarding the role of whole pelvis radiotherapy in patients with non-metastatic prostate cancer.... |
|
|
Location and Control of Local Disease Predict Overall Survival and Distant Metastases Free Survival in Patients with Ipsilateral Breast Tumor Recurrence after Breast Conserving Therapy for Stage I/II Breast Cancer
Presenter: Y. ChenPresenter's Affiliation: Radiation Oncology, Massachusetts General Hospital, Boston, MAType of Session: ScientificBackground The best approach to ipsilateral breast tumor recurrence after breast conserving surgery and... |
|
|
Lumpectomy Plus Tamoxifen or Arimidex With or Without Whole Breast Irradiation in Women with Favorable Early Breast Cancer
Presenter: R. PoetterPresenter's Affiliation: Dept. of Radiotherapy and Radiobiology, Medical University of ViennaType of Session: PlenaryBackground In treating early-stage breast cancers with favorable prognostic features, the question has been... |
|
|
Patterns of Locoregional Recurrence and Their Predictors in Rectal Cancer Patients Treated with Surgery and Chemoradiation
Presenter: T. Yu.Presenter's Affiliation: MD Andersen Cancer CenterType of Session: ScientificBackground The current standard of care for treating locally advanced rectal cancer is combined modality chemotherapy and radiation with surgical... |
|
|
Phase III Randomized Study of Adjuvant Radiation Therapy versus Observation in Patients with Pathologic T3 Prostate Cancer (SWOG 8794)
Presenter: G. P. SwansonPresenter's Affiliation: UT San AntonioType of Session: PlenaryBackground Prostate cancer patients with adverse findings at surgery have an increased risk of local failure. Although radiation in the post-prostatectomy... |
|
|
Preliminary Analysis of Cancer and Leukemia Group B (CALGB) 80003: A Phase II trial of Gemcitabine, 5-Fluorouracil (5FU) and Radiation Therapy (RT) in Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma.
Presenter: Harvey MamonPresenter's Affiliation: Dana Farber/Brigham and Women's Cancer Center, Boston, MAType of Session: ScientificBackground The median survival for locally advanced, unresectable pancreatic cancer is quite low after... |
|
|
Preoperative Chemo-radiotherapy (CT-RT) Improves Local Control in T3-T4 Rectal Cancers: Results of the FFCD 9203 Randomized Trial
Presenter: P. RomestaingPresenter's Affiliation: CHU Lyon Sud, Lyon, FranceType of Session: PlenaryBackground Based on prior studies on the role of chemo-radiation in the management of patients with locally advanced rectal cancers (LARC), there has... |
|
|
Radiation Therapy (RT) as a Chemosensitizer of Gemcitabine (G) in Patients with Metastatic/Unresectable Tumors of the Gastrointestinal (GI) Tract - a Phase I/II Study Exploring a New Treatment Paradigm
Presenter: W. F. Regine, MDPresenter's Affiliation: University of Maryland, Baltimore, MDType of Session: ScientificBackground Gemcitabine is one of the most active chemotherapy drugs for the treatment of metastatic/unresectable pancreatic... |
|
|
Surveillance Should Be the Standard Approach in Patients with Stage I Seminoma
Presenter: P. R. WardePresenter's Affiliation: Princess Margaret Hospital, Toronto, ONType of Session: ScientificBackground Management options for stage I seminoma in the adjuvant setting include radiotherapy, chemotherapy, and surveillance. Although... |
|
|
The Prognostic Value of the Epidermal Growth Factor Receptor in Locally Advanced Rectal Cancer (LARC) Patients Treated with Preoperative Chemo-radiation
Presenter: J. KimPresenter's Affiliation: Radiation Oncology, Chungnam National University, College of Medicine, Daejon, South KoreaType of Session: ScientificBackground More recently, the use of targeted agents against epidermal growth factor... |
Dr. Lin discusses head and neck cancer treatment, the potential side effects and the importance of being prepared and treated for them. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

